Cargando…

IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells

SIMPLE SUMMARY: Malignant mesothelioma (MM), a rare and aggressive tumor, is related to asbestos exposure, which mediates a chronic inflammatory process involving the cytokine IL-6. Recent studies indicate that the PD-1/PD-L1 immune-suppressive axis is a clinically relevant target for therapy. The e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carbotti, Grazia, Dozin, Beatrice, Martini, Stefania, Giordano, Chiara, Scordamaglia, Francesca, Croce, Michela, Filaci, Gilberto, Ferrini, Silvano, Fabbi, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393193/ https://www.ncbi.nlm.nih.gov/pubmed/34439164 http://dx.doi.org/10.3390/cancers13164011

Ejemplares similares

Dual Roles of IL-27 in Cancer Biology and Immunotherapy
por: Fabbi, Marina, et al.
Publicado: (2017)

Cytokine-Induced Guanylate Binding Protein 1 (GBP1) Release from Human Ovarian Cancer Cells
por: Carbotti, Grazia, et al.
Publicado: (2020)

IL-27 induces the expression of IDO and PD-L1 in human cancer cells
por: Carbotti, Grazia, et al.
Publicado: (2015)

Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells
por: Petretto, Andrea, et al.
Publicado: (2016)

IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells
por: Carbotti, Grazia, et al.
Publicado: (2017)

IL-21: A Pleiotropic Cytokine with Potential Applications in Oncology
por: Croce, Michela, et al.
Publicado: (2015)

Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition
por: Amaro, Adriana, et al.
Publicado: (2020)

Different Subcellular Localization of ALCAM Molecules in Neuroblastoma: Association with Relapse
por: Corrias, Maria Valeria, et al.
Publicado: (2010)

Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives
por: Croce, Michela, et al.
Publicado: (2019)

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
por: Rigo, Valentina, et al.
Publicado: (2017)

IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome
por: Morandi, Fabio, et al.
Publicado: (2015)

Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV
por: Filaci, Gilberto, et al.
Publicado: (2018)

How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma
por: Marseglia, Mariarosaria, et al.
Publicado: (2021)

Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD‐1 receptor
por: Tumino, Nicola, et al.
Publicado: (2019)

Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab
por: Fabbi, Marina, et al.
Publicado: (2022)

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
por: Genova, Carlo, et al.
Publicado: (2022)

Activated Leukocyte Cell Adhesion Molecule Expression and Shedding in Thyroid Tumors
por: Miccichè, Francesca, et al.
Publicado: (2011)

NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy
por: Tinterri, Corrado, et al.
Publicado: (2019)

Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines
por: Nencetti, Susanna, et al.
Publicado: (2020)

Associations of IL-27 Polymorphisms and Serum IL-27p28 Levels With Osteosarcoma Risk
por: Tang, Yu-jin, et al.
Publicado: (2014)

Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma
por: Amaro, Adriana Agnese, et al.
Publicado: (2023)

Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for In Vivo HIV Control
por: Ruiz-Riol, M., et al.
Publicado: (2017)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

Peritoneal Malignant Psammomatous Mesothelioma
por: Pusiol, Teresa, et al.
Publicado: (2010)

Generation of a Novel Regulatory NK Cell Subset from Peripheral Blood CD34(+) Progenitors Promoted by Membrane-Bound IL-15
por: Giuliani, Massimo, et al.
Publicado: (2008)

Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
por: Chiarucci, Carla, et al.
Publicado: (2020)

PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression
por: Mariotti, Francesca R., et al.
Publicado: (2018)

Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment
por: Tan, Zhiwu, et al.
Publicado: (2021)

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
por: Amaro, Adriana, et al.
Publicado: (2023)

Identification of GALNT14 as a novel neuroblastoma predisposition gene
por: De Mariano, Marilena, et al.
Publicado: (2015)

A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma
por: De Mariano, Marilena, et al.
Publicado: (2017)

Editorial: IL-27 in health and disease
por: Imamichi, Tomozumi, et al.
Publicado: (2023)

IL-27, IL-30, and IL-35: A Cytokine Triumvirate in Cancer
por: Kourko, Olena, et al.
Publicado: (2019)

Anti-Cancer Immunotherapies Targeting Telomerase
por: Negrini, Simone, et al.
Publicado: (2020)

IL‐7 is expressed in malignant mesothelioma and has a prognostic value
por: Mai, Hoa‐Le, et al.
Publicado: (2022)

Combination of PD‐1/PD‐L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma
por: van Gulijk, Mandy, et al.
Publicado: (2022)

Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos ban
por: Plato, Nils, et al.
Publicado: (2016)

Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
por: Watanabe, Takuya, et al.
Publicado: (2018)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
por: White, Michael G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p1qbftktidgro4q7pqcdp5b7hk